DNTH
Price:
$44.71
Market Cap:
$1.62B
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
Industry
Biotechnology
IPO Date
2018-06-21
Stock Exchange
NASDAQ
Ticker
DNTH
According to Dianthus Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 17.35. This represents a change of 12.51% compared to the average of 15.42 of the last 4 quarters.
The mean historical Current Ratio of Dianthus Therapeutics, Inc. over the last ten years is 11.18. The current 17.35 Current Ratio has changed 15.42% with respect to the historical average. Over the past ten years (40 quarters), DNTH's Current Ratio was at its highest in in the March 2024 quarter at 42.52. The Current Ratio was at its lowest in in the March 2017 quarter at 0.
Average
11.18
Median
12.68
Minimum
1.75
Maximum
18.42
Discovering the peaks and valleys of Dianthus Therapeutics, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 468.59%
Maximum Annual Current Ratio = 18.42
Minimum Annual Increase = -86.77%
Minimum Annual Current Ratio = 1.75
| Year | Current Ratio | Change |
|---|---|---|
| 2024 | 15.22 | -17.38% |
| 2023 | 18.42 | 84.74% |
| 2022 | 9.97 | 468.59% |
| 2021 | 1.75 | -86.77% |
| 2020 | 13.26 | 24.88% |
| 2019 | 10.62 | -23.89% |
| 2018 | 13.95 | 10.03% |
| 2017 | 12.68 | 169.10% |
The current Current Ratio of Dianthus Therapeutics, Inc. (DNTH) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
14.54
5-year avg
11.73
10-year avg
11.18
Dianthus Therapeutics, Inc.’s Current Ratio is less than Enliven Therapeutics, Inc. (32.58), greater than Taysha Gene Therapies, Inc. (10.48), greater than Sana Biotechnology, Inc. (2.47), greater than Atai Beckley N.V (7.90), greater than Nektar Therapeutics (4.24), greater than AnaptysBio, Inc. (8.68), greater than Oculis Holding AG (4.55), greater than BridgeBio Oncology Therapeutics Inc. (13.33), greater than Immatics N.V. (7.36), less than Tourmaline Bio, Inc. (24.68),
| Company | Current Ratio | Market cap |
|---|---|---|
| 32.58 | $1.27B | |
| 10.48 | $1.32B | |
| 2.47 | $1.38B | |
| 7.90 | $829.95M | |
| 4.24 | $1.17B | |
| 8.68 | $1.20B | |
| 4.55 | $1.03B | |
| 13.33 | $923.07M | |
| 7.36 | $1.44B | |
| 24.68 | $1.23B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Dianthus Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Dianthus Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is Dianthus Therapeutics, Inc.'s Current Ratio?
How is the Current Ratio calculated for Dianthus Therapeutics, Inc. (DNTH)?
What is the highest Current Ratio for Dianthus Therapeutics, Inc. (DNTH)?
What is the 3-year average Current Ratio for Dianthus Therapeutics, Inc. (DNTH)?
What is the 5-year average Current Ratio for Dianthus Therapeutics, Inc. (DNTH)?
How does the current Current Ratio for Dianthus Therapeutics, Inc. (DNTH) compare to its historical average?